< Back to previous page
Organisation
Digestive Oncology
Division
Main organisation:Department of Oncology
Lifecycle:1 Aug 2022 → Today
Organisation profile:
Digestive Oncology
Keywords:oncology
Disciplines:Oncology
Current researchers
1 - 10 of 12 results
- Sabine Tejpar (Responsible)
- Sarah Cappuyns (Member)
- Jeroen Dekervel (Member)
- Frederik Peeters (Member)
- Ting Pu (Member)
- Sabine Tejpar (Member)
- Baki Topal (Member)
- Eric Van Cutsem (Member)
- Fausto Velez Bravo (Member)
- Sara Verbandt (Member)
Projects
1 - 10 of 55
- Querying and exploiting the spatial colorectal tumor ecosystem for novel biological, diagnostic and therapeutic insightsFrom23 Nov 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The evolutionary landscape of colorectal cancer, from polyp to metastasisFrom25 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Multicenter validation trial of [18F]AlF-FAPI-74 for PET imaging of cancer-associated fibroblasts through fibroblast activation protein inhibitors (FAPI) in digestive tumorsFrom1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Optimizing a high throughput TCR-epitope recognition tool to characterize microbiome specific TCR interactions in colorectal cancerFrom1 Oct 2023 → TodayFunding: BOF - doctoral mandates
- Non-genetic drivers of YAP activation in colorectal cancerFrom26 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Study the efficacy and mechanism of targeted TIM3 and VISTA in the treatment of gastroesophageal junction / gastric cancer patients with low immunogenicity and FLOT chemotherapy resistanceFrom14 Feb 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Using mucins as friends in colorectal cancer diagnostics and treatmentFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Infrastructure for Targeted ProteomicsFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Unique IsoPlexis technology for multiplexed single cell functional profilingFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Obesity-associated Hepatocellular Carcinoma at Single Cell Resolution for Risk Prediction and Novel Therapeutics - HepatoSCRIPTFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
Publications
41 - 50 of 1022
- Association of TMB using the Foundation Medicine Companion Diagnostic (F1CDx) with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (pembro plus chemo) versus chemo in patients with gastric cancer (gc) from KEYNOTE-062(2020)
Authors: Eric Van Cutsem
Pages: S907 - S908 - A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859(2020)
Authors: Eric Van Cutsem
Pages: S1316 - S1317 - POLO: Subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer(2021)
Authors: Eric Van Cutsem
Pages: S1086 - S1087 - Efficacy and safety of surgery with curative intent in patients treated with first-line Bevacizumab plus chemotherapy for metastatic colorectal cancer: First beat(2008)
Authors: Eric Van Cutsem
Pages: I25 - I25 - GLOW: Zolbetuximab plus CAPOX compared with placebo plus CAPOX as first-line treatment for patients with Claudin18.2+/HER2-Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study(2019)
Authors: Eric Van Cutsem
- Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.(2023)
Authors: Eric Van Cutsem
Pages: 496 - 508 - Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164.(2023)
Authors: Eric Van Cutsem
Pages: 185 - 195 - Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial(2023)
Authors: Eric Van Cutsem
- CONSIGN: An open-label phase 3B study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy(2015)
Authors: Eric Van Cutsem
Pages: S378 - S379 - HALO 109-301: Phase III, randomized, double-blind, placebo-controlled study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients with previously untreated hyaluronan (HA)-high stage IV pancreatic ductal adenocarcinoma (PDA)(2018)
Authors: Eric Van Cutsem
Pages: 270 - 270